more

UnitedHealth Group (UNH)

(Real Time Quote from BATS)

$578.05 USD

-11.09 (-1.88%)

Updated Sep 17, 2024 03:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

Bottom 28% (181 out of 251)

Industry: Medical - HMOs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.

Here's Why You Should Retain Charles River (CRL) Stock for Now

by Zacks Equity Research Published on May 16,2022

Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.

Here's Why Investors Should Retain Medtronic (MDT) Stock

by Zacks Equity Research Published on May 13,2022

Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.

Here's Why You Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research Published on May 13,2022

Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.

NEOGEN (NEOG) Introduces InfiniSEEK for Cattle Breeders

by Zacks Equity Research Published on May 13,2022

NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.

Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow

by Zacks Equity Research Published on May 12,2022

Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.

STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

by Zacks Equity Research Published on May 12,2022

Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip

by Zacks Equity Research Published on May 12,2022

According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.

Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research Published on May 11,2022

Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.

earnings

Here's Why You Should Hold on to Henry Schein (HSIC) Now

by Zacks Equity Research Published on May 11,2022

Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.

Here's Why You Should Hold on to CVS Health (CVS) For Now

by Zacks Equity Research Published on May 11,2022

Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.

National Vision (EYE) Tops Q1 Earnings Estimates, Cuts '22 View

by Zacks Equity Research Published on May 11,2022

National Vision (EYE) reports better-than-expected earnings and an increase in store count for the first quarter.

Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays

by Zacks Equity Research Published on May 11,2022

Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.

Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues

by Zacks Equity Research Published on May 11,2022

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.